西罗莫司片是治什么的？

What does sirolimus tablets treat? Sirolimus is suitable for patients aged 13 or above who have received kidney transplants to prevent organ rejection. Take orally, once daily. It is recommended that rapamycin (sirolimus) be used in combination with cyclosporine and corticosteroids. Monitoring of therapeutic drug plasma concentrations is recommended for all patients receiving rapamycin (sirolimus tablets). For kidney transplant patients, the efficacy benefit of doses above 2 mg is unclear.

Rapamin (sirolimus tablets) is a triene macrolide antibiotic extracted from the culture medium of Streptomyces and is a T cell inhibitor. This product has a different mechanism of action from other immunosuppressants. This product inhibits the activation and proliferation of T lymphocytes stimulated by antigens and cytokines (interleukin IL-2, IL-4 and IL-15), and also inhibits the production of antibodies. This complex binds to the mammalian sirolimus target molecule (a regulatory kinase) and inhibits its activity, blocking the proliferation of cytokine-driven T cells, that is, inhibiting the progression from the G1 phase to the S phase in the cell cycle.

Model animal test results show that rapamin can prolong the survival of allografts (kidney, heart, skin, pancreatic islets, small intestine, pancreatico-duodenum and bone marrow) in mice, rats, pigs and/or primates. Sirolimus reverses acute rejection of cardiac and renal allografts in rats and prolongs graft survival in presensitized rats. In some studies, the immunosuppressive effects of rapamycin (sirolimus) persisted for 6 months after stopping treatment. This immune tolerance effect is alloantigen specific.

Recommended related hot articles: /newsDetail/83745.html